Infection with SARS-CoV-2 following Second Dose Pfizer-BioNTech mRNA COVID-19 Vaccine BNT162b2 in Danish Adolescents Aged 12–18 Years: A Real-World Nationwide Danish Cohort Study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Infection with SARS-CoV-2 following Second Dose Pfizer-BioNTech mRNA COVID-19 Vaccine BNT162b2 in Danish Adolescents Aged 12–18 Years : A Real-World Nationwide Danish Cohort Study. / Birk, Nina Marie; Christensen, Anne Vinggaard; Nygaard, Ulrikka; Bundgaard, Henning; Nielsen, Susanne Dam; Berg, Selina Kikkenborg; Wallach-Kildemoes, Helle.
In: Viruses, Vol. 16, 56, 2024.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Infection with SARS-CoV-2 following Second Dose Pfizer-BioNTech mRNA COVID-19 Vaccine BNT162b2 in Danish Adolescents Aged 12–18 Years
T2 - A Real-World Nationwide Danish Cohort Study
AU - Birk, Nina Marie
AU - Christensen, Anne Vinggaard
AU - Nygaard, Ulrikka
AU - Bundgaard, Henning
AU - Nielsen, Susanne Dam
AU - Berg, Selina Kikkenborg
AU - Wallach-Kildemoes, Helle
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2024
Y1 - 2024
N2 - In this real-world cohort study based on Danish nationwide registers, the cumulated proportion, relative risk (RR) of SARS-CoV-2 breakthrough infections, and vaccine effectiveness (VE) were investigated in adolescents aged 12–18 years following vaccination with the BNT162b2 vaccine compared to unvaccinated controls. Adolescents with and without vaccination with the first dose of BNT162b2 between 1 May and 30 September 2021 were included. Effect estimates include proportions with a positive SARS-CoV-2 RT-PCR test among vaccinated and unvaccinated, RR, and VE at three different time points. During Delta-dominance, VE was first 97.6% (95% CI 96.3–98.4), then 96.2% (95% CI 95.4–96.9) in the age group 12–15 and 95.1% (95% CI 94.1–96.0) followed by 95.5% (95% CI 94.8–96.1) in the age group 16–18 years, respectively. During Omicron dominance, VE was 5.8% (95% CI 4.6–7.0) in ages 12–15 years and 9.2% (95% CI 7.7–10.6) in ages 16–18 years. Thus, BNT162b2-vaccine protection was limited during the Omicron era.
AB - In this real-world cohort study based on Danish nationwide registers, the cumulated proportion, relative risk (RR) of SARS-CoV-2 breakthrough infections, and vaccine effectiveness (VE) were investigated in adolescents aged 12–18 years following vaccination with the BNT162b2 vaccine compared to unvaccinated controls. Adolescents with and without vaccination with the first dose of BNT162b2 between 1 May and 30 September 2021 were included. Effect estimates include proportions with a positive SARS-CoV-2 RT-PCR test among vaccinated and unvaccinated, RR, and VE at three different time points. During Delta-dominance, VE was first 97.6% (95% CI 96.3–98.4), then 96.2% (95% CI 95.4–96.9) in the age group 12–15 and 95.1% (95% CI 94.1–96.0) followed by 95.5% (95% CI 94.8–96.1) in the age group 16–18 years, respectively. During Omicron dominance, VE was 5.8% (95% CI 4.6–7.0) in ages 12–15 years and 9.2% (95% CI 7.7–10.6) in ages 16–18 years. Thus, BNT162b2-vaccine protection was limited during the Omicron era.
KW - adolescents
KW - BNT162b2 vaccine
KW - COVID-19
KW - real-world data
KW - vaccine effectiveness
U2 - 10.3390/v16010056
DO - 10.3390/v16010056
M3 - Journal article
C2 - 38257757
AN - SCOPUS:85183267270
VL - 16
JO - Viruses
JF - Viruses
SN - 1999-4915
M1 - 56
ER -
ID: 382448339